New research presented at the November 2006 American College of Rheumatology meeting in Washington and discussed on Aidsmap, shows that arthritis and connective tissue disease are unexpectedly more likely in people with HIV taking potent anti-HIV therapy. The two studies presented on the subject were from the U.K and the U.S. Before effective... Read more
On Wednesday, November 29, the Food and Drug Administration’s independent Arthritis Advisory Committee met to discuss the safety and efficacy of celecoxib, a nonsteriodal anti-inflammatory drug (COX-2 inhibitor). Celecoxib is marketed as Celebrex stuby Pfizer, Inc. The FDA approved the drug for use in adults with osteoarthritis and... Read more
On November 13th, the Associated Press released an article showing mixed reviews of Arcoxia, the cox-2 inhibitor drug that Merck is hoping to market as a replacement for its drug Vioxx. Merck pulled Vioxx off the market in late 2004 because of studies showing an increased risk of heart attack / cardiovascular events when taking the drug.The... Read more
In a new study published in the November 2006 issue of Arthritis and Rheumatism, scientists at the University Of Michigan Medical School reported evidence that challenges longstanding theories about the cause of rheumatoid arthritis.The focus of the study was to discover why almost 95 percent of RA patients have a common sequence of DNA (called... Read more
Last week, Phadia US Inc. announced that the U.S. Food and Drug Administration had cleared EliA (TM) CCP, the first fully automated assay for measuring cyclic citrullinated peptide (CCP) antibodies. CCP is an indicator for rheumatoid arthritis (RA) that is found in the blood. Phadia believes that this test will allow physicians to diagnose RA... Read more